PE20011030A1 - Combinaciones farmaceuticas que comprenden tegaserod y omeprazol - Google Patents

Combinaciones farmaceuticas que comprenden tegaserod y omeprazol

Info

Publication number
PE20011030A1
PE20011030A1 PE2000001312A PE0013122000A PE20011030A1 PE 20011030 A1 PE20011030 A1 PE 20011030A1 PE 2000001312 A PE2000001312 A PE 2000001312A PE 0013122000 A PE0013122000 A PE 0013122000A PE 20011030 A1 PE20011030 A1 PE 20011030A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
antagonists
receptor
anodycle
Prior art date
Application number
PE2000001312A
Other languages
English (en)
Spanish (es)
Inventor
Hans-Jurgen Pfannkuche
Stephan Anthony Billstein
Peter Dumovic
Nicola Franco
Mark Thomas Iwicki
Wilusz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20011030A1 publication Critical patent/PE20011030A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2000001312A 1999-12-10 2000-12-07 Combinaciones farmaceuticas que comprenden tegaserod y omeprazol PE20011030A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
PE20011030A1 true PE20011030A1 (es) 2001-10-31

Family

ID=23820591

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001312A PE20011030A1 (es) 1999-12-10 2000-12-07 Combinaciones farmaceuticas que comprenden tegaserod y omeprazol

Country Status (30)

Country Link
EP (3) EP1488788A1 (https=)
JP (1) JP2003523324A (https=)
KR (1) KR100765579B1 (https=)
CN (2) CN1310644C (https=)
AR (1) AR026916A1 (https=)
AT (1) ATE293971T1 (https=)
AU (2) AU778869B2 (https=)
BR (1) BR0016275A (https=)
CA (1) CA2388959A1 (https=)
CO (1) CO5261535A1 (https=)
CZ (1) CZ300690B6 (https=)
DE (1) DE60019814T2 (https=)
DK (1) DK1286668T3 (https=)
ES (1) ES2240229T3 (https=)
HU (1) HUP0301122A3 (https=)
IL (2) IL149496A0 (https=)
MX (1) MXPA02005695A (https=)
MY (1) MY133423A (https=)
NO (1) NO20022680L (https=)
NZ (2) NZ531489A (https=)
PE (1) PE20011030A1 (https=)
PL (1) PL202201B1 (https=)
PT (1) PT1286668E (https=)
RU (1) RU2264215C2 (https=)
SG (1) SG152025A1 (https=)
SK (1) SK8062002A3 (https=)
TR (1) TR200402293T2 (https=)
TW (1) TWI263496B (https=)
WO (1) WO2001041748A2 (https=)
ZA (1) ZA200204493B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284732A2 (en) * 2000-05-18 2003-02-26 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
JP2006516977A (ja) 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ,インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
WO2004105795A1 (en) * 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
AU2005261778A1 (en) * 2004-07-14 2006-01-19 Novartis Ag Combination of DPP-IV inhibitors and compounds modulating 5-HT3 and/or 5-HT4 receptors
AU2006211205A1 (en) * 2005-01-31 2006-08-10 Novartis Ag Organic compounds
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009525269A (ja) 2006-01-30 2009-07-09 ユーロ−セルティーク エス.エイ. カルシウムチャネルブロッカーとしての環状尿素化合物
CN101466368A (zh) * 2006-06-15 2009-06-24 诺瓦提斯公司 用于治疗或者预防胃损伤的仅包括替加色罗或者包括替加色罗与质子泵抑制剂组合的组合物
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US20090149433A1 (en) 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
FR3144752A1 (fr) 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362756A (en) * 1989-02-20 1994-11-08 Riviere Pierre J M Use of fedotozine in the treatment of functional states of intestinal obstructions
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
DE69226961T2 (de) * 1991-12-21 1999-04-29 Smithkline Beecham P.L.C., Brentford, Middlesex Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
US5932568A (en) * 1994-11-21 1999-08-03 Dainippon Pharmaceutical Co., Ltd. 6-methoxy-1H-benzotriazole-5-carboxamide derivatives and pharmaceutical compositions containing them
US5919760A (en) * 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
CN1409634A (zh) 2003-04-09
EP1286668A2 (en) 2003-03-05
ES2240229T3 (es) 2005-10-16
ATE293971T1 (de) 2005-05-15
SG152025A1 (en) 2009-05-29
BR0016275A (pt) 2002-08-27
JP2003523324A (ja) 2003-08-05
KR20030016208A (ko) 2003-02-26
RU2002118316A (ru) 2004-02-20
CO5261535A1 (es) 2003-03-31
PL355663A1 (en) 2004-05-04
TWI263496B (en) 2006-10-11
CZ20021967A3 (cs) 2002-08-14
HUP0301122A2 (hu) 2003-08-28
AU2005200797A1 (en) 2005-03-17
EP1286668B1 (en) 2005-04-27
CZ300690B6 (cs) 2009-07-15
EP1488788A1 (en) 2004-12-22
MXPA02005695A (es) 2002-09-18
PL202201B1 (pl) 2009-06-30
CN1875966A (zh) 2006-12-13
PT1286668E (pt) 2005-08-31
KR100765579B1 (ko) 2007-10-09
DK1286668T3 (da) 2005-08-15
NO20022680D0 (no) 2002-06-06
ZA200204493B (en) 2003-09-29
AR026916A1 (es) 2003-03-05
NZ566800A (en) 2009-11-27
CN1310644C (zh) 2007-04-18
DE60019814D1 (de) 2005-06-02
AU778869B2 (en) 2004-12-23
AU2672801A (en) 2001-06-18
NZ531489A (en) 2005-09-30
AU2005200797B2 (en) 2008-01-24
WO2001041748A3 (en) 2002-12-19
SK8062002A3 (en) 2003-04-01
RU2264215C2 (ru) 2005-11-20
EP1913944A1 (en) 2008-04-23
NO20022680L (no) 2002-08-12
HUP0301122A3 (en) 2005-03-29
IL149496A (en) 2009-12-24
IL149496A0 (en) 2002-11-10
TR200402293T2 (tr) 2004-10-21
CA2388959A1 (en) 2001-06-14
MY133423A (en) 2007-11-30
WO2001041748A2 (en) 2001-06-14
DE60019814T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
PE20011030A1 (es) Combinaciones farmaceuticas que comprenden tegaserod y omeprazol
PE20010854A1 (es) USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
PE20011265A1 (es) Novedosos derivados diamino sustituidos
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
PE20050193A1 (es) Compuestos heterociclicos utiles como activadores de nurr-1
PE20040758A1 (es) Compuestos 3-aminopirazoles n-sustituidos como inhibidores de la enzima tirosin-quinasa asociada al receptor pdgf y procedimientos para su preparacion
PE20021094A1 (es) Derivados de ciclohexano-1,4-diamina sustituidos
DK1173433T3 (da) Cyanopyrroler som progesteronreceptoragonister
ES2171675T3 (es) Derivados de diarildiamina y su uso como (ant)agonistas de los receptores delta opioides.
ATE325119T1 (de) 3-substituierte oxindol-beta-3-agonisten
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
PE20011114A1 (es) Decahidro-isoquinolinas
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
AR037065A1 (es) Una composicion farmaceutica en base a bloqueadores de receptores 5ht3 y 5ht4, inhibidores de la bomba de protones y antagonistas de receptores de h2, util para tratar los desordenes gastrointestinales
PE20060689A1 (es) Derivados de sulfonamidas como antagonistas de receptores orexina 2
PE20060604A1 (es) Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed